Login to Your Account



As Clock Ticks For Avastin Data, Genentech Faces Filing Decision

By Randall Osborne


Monday, September 9, 2002

The climate may cool with September's advent, but the industry late last week was still expecting a blast of potentially hot autumnal news about Phase III trials of Genentech Inc.'s monoclonal antibody Avastin (bevacizumab) in combination with chemotherapy against breast cancer. (Bioworld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription